Anatomy of an epidemic: Psychiatric drugs and the astonishing rise of mental illness in America

Ethical Human Psychology and Psychiatry

Volumn 7, Issue 1, 2005, Pages 23-35

  Whitaker, Robert ^a  

^a NONE   (United States)

Author keywords

Antidepressants; Antipsychotics; Epidemic; Mental illness; Schizophrenia

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; AMNESIA; ANXIETY; CLINICAL TRIAL; CONFERENCE PAPER; CONVULSION; DEPRESSIVE PSYCHOSIS; HALLUCINATION; HOSTILITY; HUMAN; IMPOTENCE; INSOMNIA; MANIA; MENTAL DISEASE; NAUSEA; NERVOUSNESS; PANIC; PRIORITY JOURNAL; SIDE EFFECT; TREMOR; UNITED STATES;

EID: 30444453131     PISSN: 15594343     EISSN: 19389000     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Ballenger, J., Burrows, G., DuPont, R., Lesser, I., Noyes, R., Pecknold, J., et al. (1988). Alprazolam in panic disorder and agoraphobia: Results from a multi-center trial. Archives of General Psychiatry, 45, 413-421.
2. Blackburn, I. M., Eunson, K., & Bishop, S. (1986). A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. Journal of Affective Disorders, 10, 67-75.
3. Bockoven, J. & Solomon, H. (1975). Comparison of two five-year follow-up studies. American Journal of Psychiatry, 132, 796-801.
4. Bola, J. & Mosher, L. (2003). Treatment of acute psychosis without neuroleptics: Two-year outcomes from the Soteria project. Journal of Nervous and Mental Disorders, 191, 219-229.
5. Bourguignon, R. (1997). Dangers of fluoxetine. The Lancet, 394, 214.
6. Breggin, P. (2003). Suicidality, violence, and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. International Journal of Risk and Safety in Medicine, 16, 31-49.
7. Carpenter, W., McGlashan, T., & Strauss, J. (1977). The treatment of acute schizophrenia without drugs: An investigation of some current assumption. American Journal of Psychiatry, 134, 14-20.
8. Chakos, M., Lieberman, J., Bilder, R., Borenstein, M., Lerner, M., Bogerts, B., et al. (1994). Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151, 1430-1436.
9. Chouinard, G., & Jones, B. (1980). Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. American Journal of Psychiatry, 137, 16-20.
10. Chouinard, G., Jones, B., & Annable, L. (1978). Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry 135, 1409-1410.
11. Dinnerstein, A., Lowenthal, M., & Blitz, B. (1966). The interaction of drugs with placebos in the control of pain and anxiety. Perspectives in Biology and Medicine, 10, 103-117.
12. Elkin, I. (1990). National Institute of Mental Health treatment of depression collaborative research program: General effectiveness of treatments. Archives of General Psychiatry, 46, 971-982.
13. Fava, G. (1994). Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychotherapy and Psychosomatics, 61, 125-131.
14. Fava, G. (2003). Can long-term treatment with antidepressant drugs worsen the course of depression? Journal of Clinical Psychiatry, 64, 123-133.
15. Gardos, G., & Cole, J. (1977). Maintenance antipsychotic therapy: Is the cure worse than the disease? American Journal of Psychiatry, 133, 32-36.
16. Greenberg, R., & Fisher, S. (1997). Mood-mending medicines: Probing drug, psychotherapy and placebo solutions. New York: John Wiley & Sons.
17. Gur, R., Cowell, P., Turetsky, B., Gallacher, F., Cannon, T., Bilker, W., et al. (1998). A follow-up magnetic resonance imaging study of schizophrenia. Archives of General Psychiatry, 55, 142-152.
18. Gur, R., Maany, V., Mozley, D., Swanson, C., Bilker, W., & Gur, R. (1998). Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. American Journal of Psychiatry, 55, 1711-1717.
19. Healy, D. Harris, M., Michael, P., Cattell, D., Savage, M., Chalasani, P., et al. (2001). Treating more patients than ever before: 1896 and 1996 compared. Unpublished manuscript.
20. Howland, R. (1966). Induction of mania with serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology, 16, 425-427.
21. Hyman, S., & Nestler, E. (1996). Initiation and adaptation: A paradigm for understanding psychotropic drug action. American Journal of Psychiatry 153, 151-161.
22. Jablensky, A., Sartorius, N., Ernberg, G., Ansker, M., Korten, A., Cooper J., et al. (1992). Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine, (Monograph Suppl. 20), 1095.
23. Jacobs, B. (1991). Serotonin and behavior: Emphasis on motor control. Journal of Clinical Psychiatry, 52 (12 Suppl.), 151-162.
24. Leff, J., Sartorius, N., Jablensky, A., Korten, A., & Ernberg, G. (1992). The international pilot study of schizophrenia: Five-year follow-up findings. Psychological Medicine, 22, 131-145.
25. Madsen, A., Keiding, A., Karle, A., Esbjerg, S., & Hemmingsen, R. (1998). Neuroleptics in progressive structural brain abnormalities in psychiatric illness. The Lancet, 352, 784-785.
26. Marks, I. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia. British Journal of Psychiatry, 162, 790-794.
27. Mathews, S., Roper, M., Mosher, L., & Menn, A. (2003). A non-neuroleptic treatment for schizophrenia: An analysis of the two-year postdischarge risk of relapse. Schizophrenia Bulletin, 5, 322-332.
28. Medical Research Council. (1965). Clinical trial of the treament of depressive illness. British Medical Journal, 881-886.
29. Moore, T. (1997, December). Hard to swallow. Washingtonian.
30. National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. (1964). Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10, 246-261.
31. Pecknold, J. C. (1988). Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial: Discontinuation effects. Archives of General Psychiatry, 45, 429-436.
32. Preda, A., MacLean, C., Mazure, C., & Bowers, M. (2001). Antidepressant-associated mania and psychosis resulting in psychiatric admission. Journal of Clinical Psychiatry, 62, 30-33.
33. Prien, R., Levine, J., & Switalski, R. (1971). Discontinuation of chemotherapy for chronic schizophrenics. Hospital Community Psychiatry, 22, 20-23.
34. Rappaport, M., Hopkins, H., Hall, K., Belleza, T., & Silverman, J. (1978). Are there schizophrenics for whom drugs may be unnecessary or contraindiciated. International Pharmacopsychiatry, 13, 100-111.
35. Satcher, D. (1999). Mental health: A report of the surgeon general. Available: www.surgeongeneral. gov/library/mentalhealth
36. Schooler, N., Goldberg, S., Boothe, H., & Cole, J. (1967). One year after discharge: Community adjustment of schizophrenic patients. American Journal of Psychiatry, 123, 986-995.
37. Shea, M., Elkin, I., Imber, S., Sotsky, S., Watkins, J., Collins, J., et al. (1992). Findings from the National Institute of Mental Health Treatment of Depression Research Program. Archives of General Psychiatry, 49, 782-787.
38. Shorter, E. (1997). A history of psychiatry. New York: John Wiley and Sons.
39. Smith, A. (1969). Studies on the effectiveness of antidepressant drugs. Pscyhopharmacology Bulletin, 5, 1-20.
40. Thomson, R. (1982). Side-effects and placebo amplification. British Journal of Psychiatry, 140, 64-68.
41. Torrey, E. F. (2001). The invisible plague: The rise of mental illness from 1750 to the present. New Brunswick, NJ: Rutgers University Press.
42. Zore, J. J., Larson, D., Lyons, J., & Beardsley, R. (1991). Expenditures for psychotropic medications in the United States in 1985. American Journal of Psychiatry, 148, 644-647.